Dr.Hua received his Ph.D. degree from the Institute of Biophysics of the Chinese Academy of Sciences in 2008. He then joined Memorial Sloan Kettering Cancer Center (MSKCC) to study the roles of intestinal stem cell during tissue regeneration, and finished his postdoctoral training at the end of 2014. Afterwards, He was recruited to Shanghai Medical School and Shanghai Cancer Center at Fudan University as a group leader. Hua Group studies the molecular mechanisms of intestinal regeneration after tissue damage and organoid-base precision medicine for cancer of various organs; Hua group optimized the organoid (normal and cancer tissues) based HTS drug screening system to identify drug candidates. Hua lab has established the largest rectal cancer organoid biobank, and demonstrated that rectal cancer patient-derived organoids can predict patient responses to neoadjuvant chemoradiation therapy. Hua group published many papers on internationally renowned journals, such as Cell Stem Cell, International Journal of Radiation Oncology/Biology/Physic, Cancer Research, Stem Cell Reports and Science China, among which the research paper published on Cell Stem Cell was selected as highly cited papers by Web of Science.

Research Focus： 

1: Tumor organoid-based precision medicine;

2: Organoid (normal and cancer tissues) based HTS drug screening；

3: The molecular mechanisms of intestinal regeneration after tissue damage;